{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:33Z","timestamp":1783075893029,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00702-015-1403-7","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T14:00:47Z","timestamp":1430748047000},"page":"1609-1617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey"],"prefix":"10.1007","volume":"122","author":[{"given":"Gudrun","family":"Hefner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E. E.","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Falter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"key":"1403_CR1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1365-2125.1981.tb01306.x","volume":"12","author":"ND Bax","year":"1981","unstructured":"Bax ND, Lennard MS, Tucker GT (1981) Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol 12:779\u2013784","journal-title":"Br J Clin Pharmacol"},{"key":"1403_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0773.1975.tb03329.x","volume":"36","author":"KO Borg","year":"1975","unstructured":"Borg KO, Carlsson E, Hoffmann KJ, Jonsson TE, Thorin H, Wallin B (1975) Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol 36:125\u2013135","journal-title":"Acta Pharmacol Toxicol"},{"key":"1403_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/00325481.1989.11704506","volume":"86","author":"RJ Cadieux","year":"1989","unstructured":"Cadieux RJ (1989) Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 86:179\u2013186","journal-title":"Postgrad Med"},{"key":"1403_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.1989.tb06430.x","volume":"352","author":"EG Christensson","year":"1989","unstructured":"Christensson EG (1989) Pharmacological data of the atypical neuroleptic compound melperone (Buronil). Acta Psychiatr Scand Suppl 352:7\u201315","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"1403_CR5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(97)00042-2","volume":"27","author":"M Eichelbaum","year":"1997","unstructured":"Eichelbaum M, Kroemer HK, Fromm MF (1997) Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev 27:171\u2013199","journal-title":"Adv Drug Deliv Rev"},{"key":"1403_CR6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","volume":"20","author":"SM Fogelman","year":"1999","unstructured":"Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480\u2013490. doi: 10.1016\/s0893-133x(98)00113-4","journal-title":"Neuropsychopharmacology"},{"key":"1403_CR7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002280050737","volume":"56","author":"T Fukuda","year":"2000","unstructured":"Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J (2000) The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 56:175\u2013180","journal-title":"Eur J Clin Pharmacol"},{"key":"1403_CR8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FTD.0b013e31828816e0","volume":"35","author":"C Geber","year":"2013","unstructured":"Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadic A (2013) Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit 35:279\u2013282. doi: 10.1097\/FTD.0b013e31828816e0","journal-title":"Ther Drug Monit"},{"key":"1403_CR9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0031-6997(25)00021-3","volume":"40","author":"FJ Gonzalez","year":"1988","unstructured":"Gonzalez FJ (1988) The molecular biology of cytochrome P450s. Pharmacol Rev 40:243\u2013288","journal-title":"Pharmacol Rev"},{"key":"1403_CR10","first-page":"329","volume":"60","author":"K Grasmader","year":"2004","unstructured":"Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML (2004) Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 60:329\u2013336. doi: 10.1007\/s00228-004-0766-8","journal-title":"Eur J Clin Pharmacol"},{"key":"1403_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2003-38084","volume":"36","author":"M Gr\u00f6zinger","year":"2003","unstructured":"Gr\u00f6zinger M, Dragicevic A, Hiemke C, Shams M, Muller MJ, H\u00e4rtter S (2003) Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry 36:3\u20136. doi: 10.1055\/s-2003-38084","journal-title":"Pharmacopsychiatry"},{"key":"1403_CR12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF02353478","volume":"24","author":"FP Guengerich","year":"1996","unstructured":"Guengerich FP (1996) In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 24:521\u2013533","journal-title":"J Pharmacokinet Biopharm"},{"key":"1403_CR13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000127","volume":"34","author":"G Hefner","year":"2014","unstructured":"Hefner G, Geschke K, Hiemke C (2014) Severe adverse drug events under combination of nortriptyline and melperone due to pharmacokinetic interaction. J Clin Psychopharmacol 34:394\u2013396. doi: 10.1097\/jcp.0000000000000127","journal-title":"J Clin Psychopharmacol"},{"key":"1403_CR14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1567201811310010008","volume":"10","author":"C Hiemke","year":"2013","unstructured":"Hiemke C, Shams M (2013) Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv 10:46\u201353","journal-title":"Curr Drug Deliv"},{"key":"1403_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"1403_CR16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","volume":"48","author":"SM Huang","year":"2008","unstructured":"Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662\u2013670. doi: 10.1177\/0091270007312153","journal-title":"J Clin Pharmacol"},{"key":"1403_CR17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2125.1990.tb03827.x","volume":"30","author":"J Kallio","year":"1990","unstructured":"Kallio J, Huupponen R, Seppala M, Sako E, Iisalo E (1990) The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. Br J Clin Pharmacol 30:638\u2013643","journal-title":"Br J Clin Pharmacol"},{"key":"1403_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00008571-199712000-00003","volume":"7","author":"D K\u00f6hler","year":"1997","unstructured":"K\u00f6hler D, H\u00e4rtter S, Fuchs K, Sieghart W, Hiemke C (1997) CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7:453\u2013461","journal-title":"Pharmacogenetics"},{"key":"1403_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-006-0098-y","volume":"62","author":"MD K\u00f6hnke","year":"2006","unstructured":"K\u00f6hnke MD, Lutz U, Wiatr G, Schwarzler F, Weller B, Schott K, Buchkremer G (2006) Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. Eur J Clin Pharmacol 62:333\u2013334. doi: 10.1007\/s00228-006-0098-y","journal-title":"Eur J Clin Pharmacol"},{"key":"1403_CR20","first-page":"1073","volume":"26","author":"R Kretzschmar","year":"1976","unstructured":"Kretzschmar R, Otto J, Teschendorf HJ, Worstmann W (1976) Pharmacological investigations of 4\u2032-fluoro-4-(4-methyl-peperidono)-butyrophenone with respect to its sedative and sleep-inducing properties (author\u2019s transl). Arzneimittelforschung 26:1073\u20131076","journal-title":"Arzneimittelforschung"},{"key":"1403_CR21","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","volume":"307","author":"MS Lennard","year":"1982","unstructured":"Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype\u2013a major determinant of metoprolol metabolism and response. N Engl J Med 307:1558\u20131560. doi: 10.1056\/nejm198212163072505","journal-title":"N Engl J Med"},{"key":"1403_CR22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/004982597240497","volume":"27","author":"DF Lewis","year":"1997","unstructured":"Lewis DF, Eddershaw PJ, Goldfarb PS, Tarbit MH (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27:319\u2013339. doi: 10.1080\/004982597240497","journal-title":"Xenobiotica"},{"key":"1403_CR23","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","volume":"71","author":"KW Lobello","year":"2010","unstructured":"Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT (2010) Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 71:1482\u20131487. doi: 10.4088\/JCP.08m04773blu","journal-title":"J Clin Psychiatry"},{"key":"1403_CR24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","volume":"33","author":"DE McAlpine","year":"2011","unstructured":"McAlpine DE, Biernacka JM, Mrazek DA, O\u2019Kane DJ, Stevens SR, Langman LJ, Courson VL, Bhagia J, Moyer TP (2011) Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 33:14\u201320. doi: 10.1097\/FTD.0b013e3181fcf94d","journal-title":"Ther Drug Monit"},{"key":"1403_CR25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","volume":"18","author":"EL Michalets","year":"1998","unstructured":"Michalets EL (1998) Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84\u2013112","journal-title":"Pharmacotherapy"},{"key":"1403_CR26","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1093\/ndt\/gfs295","volume":"27","author":"EV Nagler","year":"2012","unstructured":"Nagler EV, Webster AC, Vanholder R, Zoccali C (2012) Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 27:3736\u20133745. doi: 10.1093\/ndt\/gfs295","journal-title":"Nephrol Dial Transplant"},{"key":"1403_CR27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0024-3205(83)90315-6","volume":"32","author":"SV Otton","year":"1983","unstructured":"Otton SV, Inaba T, Kalow W (1983) Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 32:795\u2013800","journal-title":"Life Sci"},{"key":"1403_CR28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0024-3205(84)90332-1","volume":"34","author":"SV Otton","year":"1984","unstructured":"Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34:73\u201380","journal-title":"Life Sci"},{"key":"1403_CR29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2125.1989.tb03541.x","volume":"28","author":"H Perrild","year":"1989","unstructured":"Perrild H, Kayser L, Poulsen HE, Skovsted L, Jr B, Hansen JM (1989) Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance. Br J Clin Pharmacol 28:551\u2013554","journal-title":"Br J Clin Pharmacol"},{"key":"1403_CR30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2125.2011.03903.x","volume":"71","author":"TM Polasek","year":"2011","unstructured":"Polasek TM, Lin FP, Miners JO, Doogue MP (2011) Perpetrators of pharmacokinetic drug\u2013drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 71:727\u2013736. doi: 10.1111\/j.1365-2125.2011.03903.x","journal-title":"Br J Clin Pharmacol"},{"key":"1403_CR31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.pra.0000367777.96012.83","volume":"16","author":"SH Preskorn","year":"2010","unstructured":"Preskorn SH (2010) Understanding outliers on the usual dose\u2013response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. J Psychiatr Pract 16:46\u201349. doi: 10.1097\/01.pra.0000367777.96012.83","journal-title":"J Psychiatr Pract"},{"key":"1403_CR32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","volume":"24","author":"M Reis","year":"2002","unstructured":"Reis M, Lundmark J, Bjork H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 24:545\u2013553","journal-title":"Ther Drug Monit"},{"key":"1403_CR33","author":"ME Salive","year":"2013","unstructured":"Salive ME (2013) Multimorbidity in older adults. Epidemiol Rev. doi: 10.1093\/epirev\/mxs009","journal-title":"Epidemiol Rev"},{"key":"1403_CR34","unstructured":"Schmitt G, Herbold M, Peters F (2003) Methodenvalidierung im forensisch-toxikologischen Labor. Auswertung von Validierungsdaten nach den Richtlinien der GTFCh mit Valistat. Arvecon, Walldorf"},{"key":"1403_CR35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","volume":"31","author":"ME Shams","year":"2006","unstructured":"Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, H\u00e4rtter S (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493\u2013502. doi: 10.1111\/j.1365-2710.2006.00763.x","journal-title":"J Clin Pharm Ther"},{"key":"1403_CR36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"key":"1403_CR37","author":"HP Sigurdsson","year":"2014","unstructured":"Sigurdsson HP, Hefner G, Ben-Omar N, Kostlbacher A, Wenzel-Seifert K, Hiemke C, Haen E (2014) Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm. doi: 10.1007\/s00702-014-1317-9","journal-title":"J Neural Transm"},{"key":"1403_CR38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/106002809502900612","volume":"29","author":"RL Slaughter","year":"1995","unstructured":"Slaughter RL, Edwards DJ (1995) Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619\u2013624","journal-title":"Ann Pharmacother"},{"key":"1403_CR39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38:843\u2013853. doi: 10.1016\/s0531-5565(03)00133-5","journal-title":"Exp Gerontol"},{"key":"1403_CR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0032-1326769","volume":"45","author":"S Unterecker","year":"2012","unstructured":"Unterecker S, Hiemke C, Greiner C, Haen E, Jabs B, Deckert J, Pfuhlmann B (2012) The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry 45:229\u2013235. doi: 10.1055\/s-0031-1301366","journal-title":"Pharmacopsychiatry"},{"key":"1403_CR41","unstructured":"U.S. Food and Drug Administration (2014) Drug development and drug interactions: table of substrates, inhibitors and inducers. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm Accessed 19 Aug 2014"},{"key":"1403_CR42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/01.ftd.0000162868.84596.c3","volume":"27","author":"J Weide van der","year":"2005","unstructured":"van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE (2005) Metabolic ratios of psychotropics as indication of cytochrome P450 2D6\/2C19 genotype. Ther Drug Monit 27:478\u2013483","journal-title":"Ther Drug Monit"},{"key":"1403_CR43","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>3.0.CO;2-B","volume":"80","author":"RE Vestal","year":"1997","unstructured":"Vestal RE (1997) Aging and pharmacology. Cancer 80:1302\u20131310","journal-title":"Cancer"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-015-1403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-015-1403-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-015-1403-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:57:13Z","timestamp":1748375833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-015-1403-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1007\/s00702-015-1403-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]}}}